超越传统疗法:通过CLOCK/BMAL1相互作用治疗阿尔茨海默病的分子动力学
Ismail Celil Haskologlu1, Emine Erdag2, Ahmet Ozer Sehirli3
1Department of Pharmacology, Faculty of Pharmacy, Near East University, Nicosia Mersin-10, Near East Boulevard 99138, Türkiye.
Current Alzheimer research
|March 21, 2024
概括
这项研究揭示了黑激素,甲胺和多尼佩西尔与Bmal1蛋白相互作用,这表明通过将黑激素与现有或新型治疗相结合,为阿尔茨海默病 (AD) 提供了一种新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,影响认知和功能.
- 黑色素是一种昼夜节律激素,有助于分解β-粉样蛋白,并调节大脑和肌肉ARNT-Like 1 (Bmal1) 基因表达.
- 目前的AD药物如胆酶抑制剂和Lecanemab缺乏与Bmal1.1的探索联系.
研究的目的:
- 调查FDA认可的药物的分子效应 时钟:Bmal1 dimer.
- 探索将这些药物与黑激素结合用于AD治疗的潜在协同效果.
主要方法:
- 利用了分子对接和MM/PBSA方法.
- 在Bmal1结合部位内确定药物的结合亲缘关系.
- 构建的药物蛋白相互作用概况.
主要成果:
- 兰胺和多尼佩西尔的结合能量值与氨酸相似.
- 这些药物通过类似的氨基酸残留物和功能组与Bmal1相互作用.
- 梅拉托尼与Bmal1的相互作用得到证实.
结论:
- 一种新的治疗方法涉及将黑激素与Lecanemab结合起来.
- 这项研究是首次探索FDA批准的药物对Bmal1表达的影响.
- 药物组合的潜在协同效应需要进一步研究.
更多相关视频
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
10.7K
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
相关概念视频
01:22Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
01:26Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475